SCHEMBL7416044

SCHEMBL7416044

CCCCN1CC[C@H](c2ccc(N(C)C)cc2)[C@@H](COc2ccc(C(F)(F)F)cc2)C1

nearest known ligand 0.46

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 5/20 0.46
MCHR1 Q99705 1/20 0.41
HRH3 Q9Y5N1 5/20 0.40
SLC6A4 P31645 2/20 0.40
HRH2 P25021 1/20 0.37
HRH1 P35367 1/20 0.37
SLC18A2 Q05940 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAOB P27338 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7416054 1.00 SLC6A5 (0.46) SLC6A5MCHR1HRH3SLC6A4HRH2
SCHEMBL7416049 1.00 SLC6A5 (0.46) SLC6A5MCHR1HRH3SLC6A4HRH2
SCHEMBL26790183 1.00 SLC6A5 (0.46) SLC6A5MCHR1HRH3SLC6A4HRH2
Hydrochloric Acid SCHEMBL7413443 0.99 SLC6A5 (0.45) SLC6A5MCHR1HRH3SLC6A4HRH2
Hydrochloric Acid SCHEMBL7413441 0.99 SLC6A5 (0.45) SLC6A5MCHR1HRH3SLC6A4HRH2
Hydrochloric Acid SCHEMBL7413433 0.99 SLC6A5 (0.45) SLC6A5MCHR1HRH3SLC6A4HRH2
SCHEMBL7414144 0.97 SLC6A5 (0.43) SLC6A5MCHR1HRH3SLC6A4HRH2
SCHEMBL7414148 0.97 SLC6A5 (0.43) SLC6A5MCHR1HRH3SLC6A4HRH2
SCHEMBL7414146 0.97 SLC6A5 (0.43) SLC6A5MCHR1HRH3SLC6A4HRH2
SCHEMBL7418825 0.94 KDM2B (0.39) SLC6A5MCHR1HRH3SLC6A4SLC18A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0558487-B1 PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK AS (DK) 1998-10-07 EP claimed
WO-1992001672-A1 PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1992-02-06 WO claimed
US-20230346820-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 THE SCRIPPS RESEARCH INSTITUTE 2023-11-02 US disclosed
EP-0558487-B1 PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK AS (DK) 1998-10-07 EP disclosed
US-5328917-A Aminoalkyl and phenyl substituted hydrogenated pyridines NOVO NORDISK A/S (DK) 1994-07-12 US disclosed
EP-0558487-A1 PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1993-09-08 EP disclosed
WO-1992001672-A1 PIPERIDINE COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346820-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 ACE2, SARS1, ACE SLC6A5 4424/4885MCHR1 4105/4885HRH3 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.